{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:59:09Z","timestamp":1791572349925,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011581","name":"Indian Institute of Technology Indore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Structural Biology"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.crstbi.2020.12.001","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T21:41:45Z","timestamp":1607636505000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19"],"prefix":"10.1016","volume":"3","author":[{"given":"Sajjan","family":"Rajpoot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikandan","family":"Alagumuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza S.","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crstbi.2020.12.001_bib1","series-title":"WHO COVID-19 Situation Report 153","first-page":"1","year":"2020"},{"key":"10.1016\/j.crstbi.2020.12.001_bib2","doi-asserted-by":"crossref","first-page":"138996","DOI":"10.1016\/j.scitotenv.2020.138996","article-title":"Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency","volume":"730","author":"Acter","year":"2020","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.crstbi.2020.12.001_bib3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3389\/fmicb.2020.01796","article-title":"Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis","volume":"11","author":"Alexpandi","year":"2020","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.crstbi.2020.12.001_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13063-019-3846-x","volume":"21","author":"Arabi","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.crstbi.2020.12.001_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.crstbi.2020.12.001_bib6","doi-asserted-by":"crossref","first-page":"105944","DOI":"10.1016\/j.ijantimicag.2020.105944","article-title":"Teicoplanin: an alternative drug for the treatment of COVID-19?","volume":"55","author":"Baron","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.crstbi.2020.12.001_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-4939-9752-7_12","article-title":"Docking with SwissDock","volume":"2053","author":"Bitencourt-Ferreira","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"2 & 3","key":"10.1016\/j.crstbi.2020.12.001_bib8","first-page":"147","article-title":"The 2019 novel coronavirus disease (COVID-19) pandemic: a review of the current evidence","volume":"151","author":"Chatterjee","year":"2020","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.crstbi.2020.12.001_bib9","series-title":"Genomics Functional Analysis and Drug Screening of SARS-CoV-2","author":"Chen","year":"2020"},{"key":"10.1016\/j.crstbi.2020.12.001_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000Research"},{"issue":"3","key":"10.1016\/j.crstbi.2020.12.001_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.crstbi.2020.12.001_bib12","article-title":"Computer-aided prediction of biological activity spectra for chemical compounds: opportunities and limitations","volume":"1","author":"Filimonov","year":"2018","journal-title":"Biomed. Chem.: Res. Methods"},{"key":"10.1016\/j.crstbi.2020.12.001_bib13","doi-asserted-by":"crossref","first-page":"W270","DOI":"10.1093\/nar\/gkr366","article-title":"SwissDock, a protein-small molecule docking web service based on EADock DSS","volume":"39","author":"Grosdidier","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.crstbi.2020.12.001_bib14","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil. Med. Res."},{"issue":"2","key":"10.1016\/j.crstbi.2020.12.001_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/ecp.12.79","article-title":"Drug repurposing a reality: from computers to the clinic","volume":"6","author":"Issa","year":"2013","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.crstbi.2020.12.001_bib16","series-title":"Harnessing Drug Repurposing for Exploration of New Diseases: an Insight to Strategies and Case Studies, Current Molecular Medicine","author":"Jain","year":"2020"},{"issue":"1","key":"10.1016\/j.crstbi.2020.12.001_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: global mortality of the 1918-1920 \"Spanish\" influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull. Hist. Med."},{"key":"10.1016\/j.crstbi.2020.12.001_bib18","series-title":"Genomic Characterization of a Novel SARS-CoV-2","first-page":"100682","author":"Khailany","year":"2020"},{"issue":"1\u20133","key":"10.1016\/j.crstbi.2020.12.001_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejphar.2011.04.048","article-title":"PASS assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice","volume":"662","author":"Khurana","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.crstbi.2020.12.001_bib20","doi-asserted-by":"crossref","first-page":"9459047","DOI":"10.1155\/2016\/9459047","article-title":"Natural products for infectious diseases","volume":"2016","author":"Kim","year":"2016","journal-title":"Evid. based Compl. Alternative Med.: eCAM"},{"key":"10.1016\/j.crstbi.2020.12.001_bib21","doi-asserted-by":"crossref","first-page":"9837863","DOI":"10.1155\/2018\/9837863","article-title":"Natural products for the prevention and treatment of chronic inflammatory diseases: integrating traditional medicine into modern chronic diseases care","volume":"2018","author":"Kim","year":"2018","journal-title":"Evid. based Compl. Alternative Med.: eCAM"},{"issue":"2\u20133","key":"10.1016\/j.crstbi.2020.12.001_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/minf.201000151","article-title":"QSAR modelling of rat acute toxicity on the basis of PASS prediction","volume":"30","author":"Lagunin","year":"2011","journal-title":"Mol. Inf."},{"issue":"5","key":"10.1016\/j.crstbi.2020.12.001_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17460441.2019.1582639","article-title":"Are we seeing a resurgence in the use of natural products for new drug discovery?","volume":"14","author":"Li","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.crstbi.2020.12.001_bib24","first-page":"170","article-title":"[Potential antiviral therapeutics for 2019 novel coronavirus]","volume":"43","author":"Li","year":"2020","journal-title":"Zhonghua Jiehe He Huxi Zazhi\/Chin. J. Tuberc. Respir. Dis."},{"issue":"6","key":"10.1016\/j.crstbi.2020.12.001_bib25","first-page":"e79","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J.\u00a0Kor. Med. Sci."},{"issue":"1\u20133","key":"10.1016\/j.crstbi.2020.12.001_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10224","key":"10.1016\/j.crstbi.2020.12.001_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.crstbi.2020.12.001_bib28","series-title":"Leonardo, the Structural Landscape of SARS-CoV-2 Main Protease: Hints for Inhibitor Search","author":"Luigi","year":"2020"},{"issue":"7795","key":"10.1016\/j.crstbi.2020.12.001_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/d41586-020-00444-3","article-title":"More than 80 clinical trials launch to test coronavirus treatments","volume":"578","author":"Maxmen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.crstbi.2020.12.001_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2019.05.004","article-title":"Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545","volume":"168","author":"Modhiran","year":"2019","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.crstbi.2020.12.001_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J.\u00a0Nat. Prod."},{"issue":"3","key":"10.1016\/j.crstbi.2020.12.001_bib32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.crstbi.2020.12.001_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J.\u00a0Cheminf."},{"issue":"13","key":"10.1016\/j.crstbi.2020.12.001_bib34","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."},{"issue":"14","key":"10.1016\/j.crstbi.2020.12.001_bib35","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"issue":"9","key":"10.1016\/j.crstbi.2020.12.001_bib36","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"issue":"7","key":"10.1016\/j.crstbi.2020.12.001_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"Gromacs 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"Pronk","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.crstbi.2020.12.001_bib38","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: the next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.crstbi.2020.12.001_bib39","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1073\/pnas.0510851103","article-title":"Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme","volume":"103","author":"Ratia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.crstbi.2020.12.001_bib40","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev. Panam. Salud Publica\/Pan Am. J. Publ. Health"},{"key":"10.1016\/j.crstbi.2020.12.001_bib41","first-page":"2020","article-title":"Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design","author":"Rut","year":"2020","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.crstbi.2020.12.001_bib42","doi-asserted-by":"crossref","DOI":"10.4155\/fdd-2020-0010","article-title":"Drug repurposing strategies for COVID-19","volume":"2","author":"Senanayake","year":"2020","journal-title":"Future Drug Discov."},{"issue":"SI-1","key":"10.1016\/j.crstbi.2020.12.001_bib43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3906\/sag-2004-145","article-title":"Antiviral treatment of COVID-19","volume":"50","author":"Simsek Yavuz","year":"2020","journal-title":"Turk. J. Med. Sci."},{"issue":"11","key":"10.1016\/j.crstbi.2020.12.001_bib44","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15--ligand discovery for everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"16","key":"10.1016\/j.crstbi.2020.12.001_bib45","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2174\/1568026620999200517043137","article-title":"Novel drugs targeting the SARS-CoV-2\/COVID-19 machinery","volume":"20","author":"Sternberg","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.crstbi.2020.12.001_bib46","series-title":"Discovery Studio Modeling Environment, Release 2019","author":"Syst\u00e8mes","year":"2019"},{"issue":"1","key":"10.1016\/j.crstbi.2020.12.001_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3201\/eid1209.05-0979","article-title":"1918 Influenza: the mother of all pandemics","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg. Infect. Dis."},{"issue":"6","key":"10.1016\/j.crstbi.2020.12.001_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061578","article-title":"Natural products for drug discovery in the 21st century: innovations for novel drug discovery","volume":"19","author":"Thomford","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.crstbi.2020.12.001_bib49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"issue":"7","key":"10.1016\/j.crstbi.2020.12.001_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072657","article-title":"A\u00a0review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.crstbi.2020.12.001_bib51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jpha.2020.03.009","article-title":"Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants","volume":"10","author":"Ul Qamar","year":"2020","journal-title":"J.\u00a0Pharmaceut. Anal."},{"key":"10.1016\/j.crstbi.2020.12.001_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.crstbi.2020.12.001_bib53","series-title":"Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) through Computational Drug Repurposing Study, ChemRxiv : the Preprint Server for Chemistry","author":"Wang","year":"2020"},{"issue":"3","key":"10.1016\/j.crstbi.2020.12.001_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.crstbi.2020.12.001_bib55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Biosci. Trends"},{"issue":"7798","key":"10.1016\/j.crstbi.2020.12.001_bib56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A\u00a0new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.crstbi.2020.12.001_bib57","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.crstbi.2020.12.001_bib58","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3389\/fmicb.2019.02638","article-title":"Evans blue inhibits HBV replication through a dual antiviral mechanism by targeting virus binding and capsid assembly","volume":"10","author":"Xiao","year":"2019","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.crstbi.2020.12.001_bib59","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.02114-07","article-title":"Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design","volume":"82","author":"Xue","year":"2008","journal-title":"J.\u00a0Virol."},{"issue":"3","key":"10.1016\/j.crstbi.2020.12.001_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10930-020-09901-4","article-title":"The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19","volume":"39","author":"Yoshimoto","year":"2020","journal-title":"Protein J."},{"issue":"6489","key":"10.1016\/j.crstbi.2020.12.001_bib61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"}],"container-title":["Current Research in Structural Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2665928X20300258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2665928X20300258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:35:30Z","timestamp":1762940130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2665928X20300258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":61,"alternative-id":["S2665928X20300258"],"URL":"https:\/\/doi.org\/10.1016\/j.crstbi.2020.12.001","relation":{},"ISSN":["2665-928X"],"issn-type":[{"value":"2665-928X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19","name":"articletitle","label":"Article Title"},{"value":"Current Research in Structural Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crstbi.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}